The North America Insomnia Market would witness market growth of 2.8% CAGR during the forecast period (2022-2028).
Insomnia and a person's mental health are frequently linked. The insomnia industry is driven by non-pharmacological therapies that improve a person's mental state, such as yoga, hypnotherapy, and cognitive behavioral therapy. Besides that, the demand for sleeping aid devices has increased as more people experience physical difficulties while sleeping, like snoring. These sleep aids are part of the non-pharmacological insomnia medical devices, which is helping the market for treating insomnia grow.
The demand for insomnia treatment has also increased due to the advancement of technology in the healthcare and lifestyle sectors. Health watches and advanced mobile phone software are now on the market, and both are intended to help users keep track of their sleeping patterns. These cutting-edge programs have made a significant difference in user diagnosis and sleep aid. Therefore, the easy accessibility of such cutting-edge software and equipment aids in the market's expansion.
Based on a data sheet revised in November 2021 by the National Institute of Neurological Disorders and Stroke, between 135,000 and 200,000 Americans suffer from narcolepsy. However, given how frequently this condition is misdiagnosed, the actual number could be much higher. According to news reports from September 2021, a phase 3 study also demonstrated that sodium oxybate in an extended-release form helps narcolepsy patients by reducing daytime sleepiness and preventing muscle weakness.
Improved insomnia treatment outcomes in the United States will lead to a rise in the acceptance of these therapies, which will drive the growth of this market in that nation. The increase in funding for research and development in this region is also anticipated to fuel future market expansion in this region.
The US market dominated the North America Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,567 million by 2028. The Canada market is witnessing a CAGR of 4.7% during (2022 - 2028). Additionally, The Mexico market is estimated to witness a CAGR of 4.5% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Insomnia Market is Estimated to reach $5.7 Billion by 2028, at a CAGR of 3.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
By Therapy Type
- Pharmacological
- Non-Pharmacological
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Eisai Co., Ltd.
- Merck Group
- Pfizer, Inc.
- Vanda Pharmaceuticals, Inc.
- Cadila Healthcare Ltd. (Zydus Cadila)
- Sanofi S.A.
- Viatris, Inc.
- Takeda Pharmaceutical Company Limited
- Purdue Pharma L.P.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Insomnia Market, by Distribution Channel
1.4.2 North America Insomnia Market, by Therapy Type
1.4.3 North America Insomnia Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. North America Insomnia Market by Distribution Channel
4.1 North America Hospital Market by Country
4.2 North America Retail Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Insomnia Market by Therapy Type
5.1 North America Pharmacological Market by Country
5.2 North America Non-Pharmacological Market by Country
Chapter 6. North America Insomnia Market by Country
6.1 US Insomnia Market
6.1.1 US Insomnia Market by Distribution Channel
6.1.2 US Insomnia Market by Therapy Type
6.2 Canada Insomnia Market
6.2.1 Canada Insomnia Market by Distribution Channel
6.2.2 Canada Insomnia Market by Therapy Type
6.3 Mexico Insomnia Market
6.3.1 Mexico Insomnia Market by Distribution Channel
6.3.2 Mexico Insomnia Market by Therapy Type
6.4 Rest of North America Insomnia Market
6.4.1 Rest of North America Insomnia Market by Distribution Channel
6.4.2 Rest of North America Insomnia Market by Therapy Type
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.1.5.2 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
7.3.4.1 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Acquisition and Mergers:
7.9.2.2 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview
TABLE 1 North America Insomnia Market, 2018 - 2021, USD Million
TABLE 2 North America Insomnia Market, 2022 - 2028, USD Million
TABLE 3 North America Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 4 North America Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 5 North America Hospital Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Hospital Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Retail Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Retail Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 12 North America Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 13 North America Pharmacological Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Pharmacological Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Non-Pharmacological Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Non-Pharmacological Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Insomnia Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Insomnia Market by Country, 2022 - 2028, USD Million
TABLE 19 US Insomnia Market, 2018 - 2021, USD Million
TABLE 20 US Insomnia Market, 2022 - 2028, USD Million
TABLE 21 US Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 22 US Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 23 US Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 24 US Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 25 Canada Insomnia Market, 2018 - 2021, USD Million
TABLE 26 Canada Insomnia Market, 2022 - 2028, USD Million
TABLE 27 Canada Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 28 Canada Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 29 Canada Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 30 Canada Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 31 Mexico Insomnia Market, 2018 - 2021, USD Million
TABLE 32 Mexico Insomnia Market, 2022 - 2028, USD Million
TABLE 33 Mexico Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 34 Mexico Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 35 Mexico Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 36 Mexico Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 37 Rest of North America Insomnia Market, 2018 - 2021, USD Million
TABLE 38 Rest of North America Insomnia Market, 2022 - 2028, USD Million
TABLE 39 Rest of North America Insomnia Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 40 Rest of North America Insomnia Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 41 Rest of North America Insomnia Market by Therapy Type, 2018 - 2021, USD Million
TABLE 42 Rest of North America Insomnia Market by Therapy Type, 2022 - 2028, USD Million
TABLE 43 Key Information – Eisai Co., Ltd.
TABLE 44 Key Information – Takeda Pharmaceutical Company Limited
TABLE 45 Key Information – Vanda Pharmaceuticals, Inc.
TABLE 46 Key Information – Cadila Healthcare Ltd.
TABLE 47 Key Information – Sanofi S.A.
TABLE 48 key Information – Merck GrouP
TABLE 49 Key Information – Pfizer, Inc.
TABLE 50 key information – Viatris, Inc.
TABLE 51 Key Information – Currax Pharmaceuticals LLC
TABLE 52 Key Information – Purdue Pharma L.P.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Eisai Co., Ltd.
FIG 3 Recent strategies and developments: Currax Pharmaceuticals LLC